Search research articles
Contact Us
Filters
Showing results (1-10 of 92) with videos related to
Page
of 10
Sort By:
The New England Journal of Medicine
|
April 29, 2026
Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply
Otto Metzger
Dermatology Research and Practice
|
January 5, 2012
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
Felipe Ades, Otto Metzger-Filho
Cancer Cell
|
October 20, 2012
SnapShot: breast cancer
Kornelia Polyak, Otto Metzger Filho
Therapeutic Advances in Medical Oncology
|
August 3, 2016
Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications
Romualdo Barroso-Sousa, Otto Metzger-Filho
Journal of the National Cancer Institute. Monographs
|
November 2, 2011
Neoadjuvant chemotherapy and targeted therapies: a promising strategy
Otto Metzger-Filho, Evandro de Azambuja
Nature Reviews. Clinical Oncology
|
August 9, 2017
Breast cancer: T-DM1 - an important agent in the history of breast cancer management
Otto Metzger-Filho, Eric P Winer
Current Opinion in Oncology
|
May 21, 2010
First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions
Otto Metzger-Filho, Camilo Moulin, Veronique D'Hondt
Expert Opinion on Investigational Drugs
|
April 9, 2010
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends
Otto Metzger-Filho, Tushar Vora, Ahmad Awada
Current Clinical Pharmacology
|
April 22, 2010
Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives
Otto Metzger-Filho, Camilo Moulin, Ahmad Awada
Future Oncology (London, England)
|
August 12, 2009
Changing the clinical picture of challenging tumors: tales becoming reality?
Camilo Moulin, Otto Metzger-Filho, Ahmad Awada
Page
of 10
Search research articles
Search
Showing results (1-10 of 92) with videos related to
Sort By:
Page
of 10
The New England Journal of Medicine
|
April 29, 2026
Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply
Otto Metzger
Dermatology Research and Practice
|
January 5, 2012
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
Felipe Ades, Otto Metzger-Filho
Cancer Cell
|
October 20, 2012
SnapShot: breast cancer
Kornelia Polyak, Otto Metzger Filho
Therapeutic Advances in Medical Oncology
|
August 3, 2016
Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications
Romualdo Barroso-Sousa, Otto Metzger-Filho
Journal of the National Cancer Institute. Monographs
|
November 2, 2011
Neoadjuvant chemotherapy and targeted therapies: a promising strategy
Otto Metzger-Filho, Evandro de Azambuja
Nature Reviews. Clinical Oncology
|
August 9, 2017
Breast cancer: T-DM1 - an important agent in the history of breast cancer management
Otto Metzger-Filho, Eric P Winer
Current Opinion in Oncology
|
May 21, 2010
First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions
Otto Metzger-Filho, Camilo Moulin, Veronique D'Hondt
Expert Opinion on Investigational Drugs
|
April 9, 2010
Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends
Otto Metzger-Filho, Tushar Vora, Ahmad Awada
Current Clinical Pharmacology
|
April 22, 2010
Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives
Otto Metzger-Filho, Camilo Moulin, Ahmad Awada
Future Oncology (London, England)
|
August 12, 2009
Changing the clinical picture of challenging tumors: tales becoming reality?
Camilo Moulin, Otto Metzger-Filho, Ahmad Awada
Page
of 10